Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.68 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.68 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.68 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | CNR2 | P34972 | 3/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22055472 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| N-Cyclopentyldecanamide SCHEMBL692378 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL27755204 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| Hexadecanoic Acid Cyclopentylamide SCHEMBL1456473 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL11525129 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL1456736 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL28342770 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL931252 | 0.98 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL21443012 | 0.96 | SMN1; SMN2 (0.75) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| Hexadecanoic Acid Cyclohexylamide SCHEMBL1456860 | 0.96 | SMN1; SMN2 (0.75) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | SMN1; SMN2 610/4885HDAC3 216/4885HDAC1 51/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | SMN1; SMN2 3634/4885HDAC3 238/4885HDAC1 184/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | SMN1; SMN2 2003/4885HDAC3 1354/4885HDAC1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.